Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | CPS1 | P31327 | 2/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1447539 | 0.87 | ALDH1A1 (0.57) | HTTALDH1A1TSHRCPS1HSD11B1 | |
| SCHEMBL3198514 | 0.80 | ALDH1A1 (0.51) | HTTHPGDALDH1A1HSD11B1 | |
| SCHEMBL14661603 | 0.79 | POLB (0.53) | HPGDALDH1A1TSHRL3MBTL1POLB | |
| SCHEMBL3187945 | 0.77 | KMT2A (0.45) | HPGDALDH1A1HSD11B1L3MBTL1LMNA | |
| SCHEMBL1447932 | 0.76 | OXTR (0.61) | HTTHPGDALDH1A1TSHRPOLB | |
| SCHEMBL7871104 | 0.76 | HPGD (0.63) | HTTHPGDALDH1A1TSHRGFER | |
| SCHEMBL1447972 | 0.76 | ALDH1A1 (0.63) | HTTHPGDALDH1A1TSHRGFER | |
| SCHEMBL22444626 | 0.75 | ALDH1A1 (0.45) | HTTHPGDALDH1A1HSD11B1LMNA | |
| SCHEMBL15286110 | 0.75 | ALDH1A1 (0.61) | HTTHPGDALDH1A1TSHRGFER | |
| SCHEMBL21650784 | 0.75 | ALDH1A1 (0.61) | HTTHPGDALDH1A1TSHRGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| EP-1912974-A1 | IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015064-A1 | IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | CCNI, MKI67, TYMP | HTT 3458/4885HPGD 327/4885ALDH1A1 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.